CoChat

Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open‐Label Transition From Reference Infliximab to Biosimilar Infliximab

Tweehuysen, Lieke, van den Bemt, Bart J. F., van Ingen, Iris L., de Jong, Alphons J. L., van der Laan, Willemijn H., van den Hoogen, Frank H. J., den Broeder, Alfons A. · 2018 · Arthritis & Rheumatology
Cited by 164

The DOI matches its Crossref record.

Abstract

Objective: To evaluate drug survival, effectiveness, pharmacokinetics, immunogenicity, and safety in daily practice after transitioning treatment from original reference infliximab (Remicade [REM]) to a biosimilar infliximab (CT‐P13 [Remsima; Inflectra]) in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Methods: Of the initial 222 REM‐treated patients, 192 agreed to transition to CT‐P13 and were included in this multicenter prospective cohort study. Changes in the Disease Activity Score in 28 joints using the C‐reactive protein level (DAS 28‐CRP) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and changes in the CRP levels, infliximab trough levels, and anti‐infliximab antibody levels were assessed after 6 months, and adverse events (AE s) were documented. Drug survival and prognostic factors were analyzed using Kaplan‐Meier and Cox regression analyses. Results: During 6 months follow‐up, 24% of the patients (n = 47) discontinued CT‐P13. Thirty‐seven patients restarted REM, 7 switched to another biologic drug, and 3 continued without a biologic drug. The DAS 28‐CRP remained stable from baseline to month 6, with a mean ± SD score of 2.2 ± 0.9 at baseline to 2.2 ± 0.8 at 6 months (difference of 0.0 [95% confidence interval (95% CI) –0.1, 0.2]). The BASDAI increased from a mean ± SD of 3.8 ± 2.0 at baseline to 4.3 ± 2.1 at 6 months (difference of +0.5 [95% CI 0.1, 0.9]). The CRP levels, infliximab trough levels, and anti‐infliximab antibody levels did not change. Just prior to CT‐P13 discontinuation, the DAS 28‐CRP components tender joint count and patient's global assessment of disease activity, as well as the BASDAI were increased compared to baseline. The most frequently reported AE s were arthralgia, fatigue, pruritus, and myalgia. A shorter REM infusion interval (hazard ratio: 0.77 [95% CI 0.62, 0.95]) at baseline was predictive of discontinuing CT‐P13. Conclusion: In our cohort, one‐fourth of patients discontinued CT‐P13 during 6 months of follow‐up, mainly due to an increase in the subjective features of the tender joint count and the patient's global assessment of disease activity and/or subjective AE s, possibly explained by nocebo effects and/or incorrect causal attribution effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.40324

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Metadata

Authors
Tweehuysen, L., van den Bemt, B. J. F., van Ingen, I. L., de Jong, A. J. L., van der Laan, W. H., van den Hoogen, F. H. J., & den Broeder, A. A.
Venue
Arthritis & Rheumatology
Publisher
Wiley
Published
2017-12-07
Volume
70
Issue
1
Pages
60-68
ISSN
  • 2326-5191 (ISSN-L)
  • 2326-5205
OpenAlex
W2766388803
Cited by
164
References
0
FWCI
9.84
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open‐Label Transition From Reference Infliximab to Biosimilar Infliximab. https://app.cochat.ai/papers/10.1002/art.40324
The paper
Tweehuysen, L., van den Bemt, B. J. F., van Ingen, I. L., de Jong, A. J. L., van der Laan, W. H., van den Hoogen, F. H. J., & den Broeder, A. A. (2018). Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open‐Label Transition From Reference Infliximab to Biosimilar Infliximab. Arthritis & Rheumatology. https://doi.org/10.1002/art.40324

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.